Table 1.

Cases of antibody-mediated rejection treated with eculizumab.

	Patients	Regimen	Outcome
Locke et al. (2009) [5]	20-yo male Bone marrow transplant Positive DSA Positive crossmatch	1 dose (600 mg)	Improvement in allograft function and AMR resolution in biopsy
Lonze et al. (2010) [6]	43-yo female Kidney pair exchange Positive DSA Positive crossmatch	8 doses (1200 mg × 4, 600 mg × 4)	Normalization of allograft function
González-Roncero et al. (2012) [7]	2 cases 49-yo male and 34 yo female Low immunological risk	1 dose (600 mg)	Improvement in allograft function
Noone et al. (2012) [8]	13-yo female High immunological risk Factor H deficiency	2 doses (600 mg, 900 mg)	Improvement in allograft function
Stewart et al. (2012) [9]	29-yo male ABO incompatibility	5 doses	Improvement in allograft function and resolution of AMR in biopsy
Kocak et al. (2013) [10]	2 cases 26-yo female and 46-yo female Positive DSA	5 doses (5 × 900 mg)	Improvement in allograft function (only 1 recipient)
Burbach et al. (2014) [12]	2 cases 43-yo female and 36-yo male Positive DSA Negative C4d in biopsy	6 doses (900 mg × 4, 1200 mg × 2)	No improvement in allograft function
Chehade et al. (2015) [11]	7-yo male Positive DSA	2 doses (600 mg × 2)	Normalization of allograft function
Current case (2015)	50-yo female Pretransplant positive DSA Negative C4d in biopsy	3 doses (1200 mg × 1, 900 mg × 2)	Transient stabilization of allograft function Persistence of AMR in repeated biopsy

DSA: donor specific antibody.

yo: year-old.

AMR: antibody-mediated rejection.